TGFB2 and neoplasm: The combination of tumour antigen-specific induction via MART1 with the non-specific immune stimulation via GM-CSF and shTGF-β2-mediated anti-tumour effects in presence of the oncolytic adenovirus was more potent than the anti-tumour effects of individual treatments (MART1 or GM-CSF/shRNA of TGF-β2).